Initial Combination of Gemigliptin and Metformin on Microbiota Change

• Status: Completed
• Trial end date: 2021-03-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate gut microbiota change and glucose lowering effect of initial combination therapy of gemigliptin and metformin compared to glimepiride and metformin in obese patients with type 2 diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Treatments: Glimepiride; Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Drug naive (no anti-diabetic medication within 6 weeks)

• HbA1c >= 7.5%

• BMI >= 25.0 kg/m2

Exclusion Criteria:

• Type 1 diabetes

• DKA, HHS

• history of hypersensitivity to sulphonylurea, metformin or DPP-4 inhibitor

• Gestational diabetes mellitus

• Serum Cr >1.5 mg/dL (male), >1.4mg/dL (female)

• Abnormal liver function test

• Anti-obesity medication within 3 months

• Gastrointestinal motility drug, laxatives within 3 months

• History of major gastrointestinal surgery